Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.

@article{Agesen2018EffectOI,
  title={Effect of Insulin Analogs on Frequency of Non-Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucose-The HypoAna Trial.},
  author={Rikke Mette Agesen and Peter Lommer Kristensen and Henning Beck-Nielsen and Kirsten N{\o}rgaard and Hans Perrild and Tonny J Jensen and Henrik Parving and Birger Thorsteinsson and Lise Tarnow and Ulrik Pedersen-Bjergaard},
  journal={Diabetes technology & therapeutics},
  year={2018},
  volume={20 3},
  pages={
          247-256
        }
}
BACKGROUND Hypoglycemia is an increasingly important endpoint in clinical diabetes trials. The assessment of hypoglycemia should therefore be as complete as possible. Blinded continuous glucose monitoring (CGM) provides an improved opportunity to capture asymptomatic and nocturnal events. Here we report results from the HypoAna trial comparing all-analog-insulin therapy (aspart/detemir) with all-human-insulin therapy (neutral protamine Hagedorn/regular) on non-severe hypoglycemia (symptomatic… CONTINUE READING
BETA